Investment surges, hurdles and emerging innovations in neuroscience
Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in the field.
Healthcare
Astellas withdraws Europe ACP application for AMD treatment
Takeda and BMC partner to decarbonise US healthcare sector
CPHI Europe: how AI can drive growth in the nutraceutical space
CPHI Europe: strategies to navigate nitrosamines risk evaluation
DPV set to acquire Lumos Pharma for $38m
TheracosBio and BAMCO to bring BRENZAVVY to sub-Saharan Africa for T2D
Health Canada approves Acadia’s DAYBUE for Rett syndrome
